Click here to learn more!
| This week's FierceBiotech is brought to you by IQVIA.
Trouble viewing? Click here. |
|
| In a recent Phase III Type I diabetes trial, IQVIA faced aggressive timelines to meet a submission deadline. IQVIA accelerated site identification and patient recruitment to help our customer meet the critical regulatory filing dates. |
|
| IQVIA Core-Powered Clinical Development |
| Our CORE-powered approach to clinical development dramatically increases speed and efficiency to help you bring your products to patients faster. Accelerate site identification by up to 40% Increase patient enrollment by up to 30% Applied to more than 200 clinical studies |
Proof, not promises
|
|
| Data based on a recent Phase III Type I diabetes trial. Comparisons based on previous studies in the same indication and geographies conducted by IQVIA. Results may vary due to various factors. |
